This siRNA-based immune checkpoint silencing system could fundamentally inhibit the secretion of PD-L1 from tumor cells into the tumor microenvironment, leading to an increased immune response compared with antibody-based blockades (figure 1A). Here, CD274 is linked to neoplasm.